Neogen Reports Q3 2024 Revenue of $228.8M

Neogen Corporation (NASDAQ: NEOG) has released its third-quarter 2024 results, reporting a revenue of $228.8 million. The company experienced a net loss of $(2.0) million, equivalent to $(0.01) per diluted share, while the adjusted net income stood at $26.4 million, or $0.12 per diluted share. Adjusted EBITDA for the quarter was $52.7 million.

In terms of revenue, Neogen saw an increase of 4.8% compared to the prior year, with core revenue, excluding certain impacts, showing a 6.2% growth. The gross margin for the quarter was 51.1%, up from 49.5% in the same period the previous year, primarily due to increased sales of higher-margin products in the food safety segment.

The food safety segment contributed revenues of $157.8 million, marking a 4.1% increase from the prior year. The animal safety segment also showed growth, with revenues of $71.1 million, up by 6.5% from the previous year.

However, the company faced operational inefficiencies affecting order fulfillment rates due to the integration of the former 3M food safety business, resulting in a slower-than-anticipated recovery of order fulfillment rates. As a result, the full-year revenue outlook has been adjusted to a range of $910 million to $920 million, with adjusted EBITDA expected to be in the range of $210 million to $215 million.

Neogen Corporation remains committed to rectifying the present level of inefficiencies and ultimately realizing the long-term benefits of the merger with the former 3M food safety division.

As of February 29, 2024, the company held total cash and investments of $168.4 million and total outstanding non-current debt of $900.0 million, with committed borrowing headroom of $150.0 million.

As a result of these announcements, the company's shares have moved 0.2% on the market, and are now trading at a price of $14.38. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.